Founding Editor

Owen Calder

Owen Calder approaches GLP-1 coverage through drug-development and healthcare-finance experience. He explains the evidence behind treatments and the practical differences between prescribing services, medication access and ongoing costs.

Editorial role · Not a licensed clinician

Clinical statements are supported by published research and named regulatory sources. This publication does not provide personal medical advice.

Read our editorial policy

From Owen Calder

Medications

Semaglutide vs tirzepatide: what the direct trial answers

The strongest comparison concerns specific injectable doses, a defined population and 72 weeks of follow-up.

Owen Calder

Appetite

Food noise: what GLP-1 studies actually measure

Cravings, hunger and control of eating overlap with the popular term, but they are not interchangeable endpoints.

Owen Calder

Body composition

Lean mass during GLP-1 treatment: read beyond the headline

DEXA lean tissue, skeletal muscle and physical ability answer different questions.

Owen Calder

Side effects

Constipation on GLP-1 treatment: frequency and follow-up

A common adverse event still needs a plan, especially when symptoms persist or change.

Owen Calder

Side effects

Fatigue during GLP-1 treatment: what the evidence can explain

A reported adverse event is a starting point for assessment, not a complete explanation.

Owen Calder

Maintenance

Weight regain after stopping GLP-1 treatment

Withdrawal trials support planning for continuity, while leaving individual outcomes uncertain.

Owen Calder

Heart health

GLP-1 cardiovascular benefits: who SELECT actually studied

Relative risk, absolute difference and baseline cardiovascular disease all matter.

Owen Calder

Medications

Oral vs injectable GLP-1 treatment in 2026

Start with the exact product: route alone does not define evidence, instructions or coverage.

Owen Calder